Vaso (VASO) AI Stock Analysis

• Market Cap: $31.58M
• Dividend Yield: N/A
• Average Volume (3M): 98.46K
• Price to Earnings (P/E): 12.2
• Beta (1Y): 0.32
• Revenue Growth: 9.14%
• EPS Growth: N/A
• Country: US
• Employees: 298
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.01
• Shares Outstanding: 175,953,030
• 10 Day Avg. Volume: 66,687
• 30 Day Avg. Volume: 98,461
• PEG Ratio: -0.28
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.24
• P/FCF Ratio: 11.50
• Enterprise Value/Market Cap: -0.01
• Enterprise Value/Revenue: >-0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $0.20 ▲(18.82% Upside)
• Action: Downgraded Date: 12/20/25
• Date: Action: Downgraded 12/20/25

Vaso's overall stock score reflects a balance of strong financial stability and attractive valuation, tempered by operational inefficiencies and overbought technical indicators. The strategic sale of a subsidiary and shareholder support are positive, but the lack of earnings call data limits further insights.

Positive Factors

Strong balance sheet / low leverage

Very low leverage and a robust equity base reduce financial risk and increase resilience to downturns. Improved ROE shows management can generate returns from capital. This durability supports long-term investments in product development and protects against liquidity shocks.

Improving free cash flow generation

Sustained FCF growth and FCF exceeding reported earnings indicate strong cash conversion and internal funding capacity. Durable cash generation funds R&D, device production, and subscriptions expansion without heavy external financing, improving strategic optionality.

Strategic divestiture of non-core unit

Selling a small, non-core reseller unit sharpens strategic focus on telehealth, devices, and analytics. The proceeds and management bandwidth can be redeployed into higher-margin core offerings, improving long-term operational focus and capital efficiency.

Negative Factors

Negative net profit margin

A persistent negative net margin undermines sustainable profitability even if gross margins are healthy. Over time this can deplete reserves, limit reinvestment capacity, and force difficult trade-offs between growth and cost control unless operating profits are restored.

Declining EBIT / EBITDA margins

Falling operating margins point to structural cost or efficiency weaknesses in scaling the business. If not addressed, these inefficiencies will compress operating cash flows, restrict margin expansion from subscription scale, and hamper competitiveness long term.

Modest revenue growth rate

Low single-digit top-line growth limits scale benefits for a subscription and device business. Structural growth below peer expectations increases reliance on margin improvements or M&A to create shareholder value and raises execution risk over the next several quarters.

Vaso Business Overview & Revenue Model

Company Description

Vaso (VASO) is a technology-driven company focused on providing innovative solutions in the healthcare and medical sectors. The company specializes in developing advanced telehealth platforms and medical products that enhance patient care and streamline healthcare operations. Vaso's core offerings include telemedicine software, remote monitoring devices, and health data analytics services that cater to healthcare providers, patients, and medical institutions.

How the Company Makes Money

Vaso generates revenue through multiple streams, primarily by offering subscription-based services for its telehealth platforms, which healthcare providers pay for to access and utilize the technology in their practices. Additionally, the company earns income from the sale of its medical devices and remote monitoring equipment. Key partnerships with healthcare organizations and technology companies enhance Vaso's reach and capabilities, further contributing to its revenue through collaborative projects and joint ventures. Furthermore, Vaso may also explore funding opportunities, grants, and investments in healthcare innovations that bolster its financial performance.

Vaso Financial Statement Overview

Summary

Vaso's financial performance shows stable revenue growth and strong equity, but the negative net profit margin raises concerns about profitability. The company has low leverage, which reduces financial risk, but operational inefficiencies are evident in declining EBIT and EBITDA margins.

Income Statement

Vaso's income statement shows a stable revenue growth rate of 2.17% TTM, indicating consistent performance. However, the net profit margin has turned negative in the TTM period, suggesting challenges in maintaining profitability. The gross profit margin remains healthy at approximately 59.77%, but the declining EBIT and EBITDA margins highlight potential operational inefficiencies.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio of 0.11 TTM, indicating financial stability and low leverage risk. Return on equity has improved to 9.49% TTM, showcasing effective use of equity to generate profits. The equity ratio is robust, further emphasizing the company's solid financial foundation.

Cash Flow

Vaso's cash flow statement reveals a significant improvement in free cash flow growth at 11.88% TTM, demonstrating enhanced cash generation capabilities. The operating cash flow to net income ratio is moderate, suggesting reasonable cash conversion efficiency. The free cash flow to net income ratio exceeds 1, indicating strong cash flow relative to earnings.

Breakdown	TTM	Mar 2025	Mar 2024	Dec 2022	Dec 2021	Mar 2021
Income Statement
Total Revenue	89.11M	86.77M	81.02M	80.02M	75.58M	69.85M
Gross Profit	54.28M	52.05M	50.59M	48.48M	43.13M	38.57M
EBITDA	3.60M	2.10M	5.95M	8.38M	6.66M	3.23M
Net Income	2.59M	951.00K	4.80M	11.87M	6.10M	358.00K
Balance Sheet
Total Assets	84.47M	82.94M	75.76M	72.66M	52.36M	50.38M
Cash, Cash Equivalents and Short-Term Investments	34.86M	26.27M	25.32M	20.32M	6.65M	7.58M
Total Debt	2.81M	2.38M	2.06M	1.81M	1.39M	13.19M
Total Liabilities	56.24M	55.24M	48.91M	49.78M	41.05M	45.29M
Stockholders Equity	28.24M	27.70M	26.84M	22.88M	11.31M	5.08M
Cash Flow
Free Cash Flow	8.79M	1.83M	4.57M	13.85M	7.40M	4.93M
Operating Cash Flow	8.64M	3.28M	5.30M	14.42M	7.82M	5.93M
Investing Cash Flow	-865.00K	11.73M	-5.66M	-8.42M	-260.00K	-575.00K
Financing Cash Flow	224.00K	-89.00K	-134.00K	-230.00K	-8.33M	-553.00K

Vaso Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VASO, the sentiment is Positive. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.17, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.67 is Neutral, neither overbought nor oversold. The STOCH value of 41.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VASO.

Vaso Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VASO	68 Neutral	$31.58M	12.18	-1.14%	―	9.14%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAT	43 Neutral	$56.97M	-2.20	-792.01%	―	―	4.31%
HCTI	41 Neutral	$4.44M	―	-182.56%	―	-21.88%	68.40%
VSEE	38 Underperform	$14.50M	-0.45	―	―	187.24%	82.90%

Vaso Corporate Events

Vaso shareholders reelect directors and adopt triennial say-on-pay

At its Annual Meeting of Shareholders held on December 17, 2025, Vaso Corporation’s shareholders elected three Class II directors—Behnam Movaseghi, Jane Moen, and Leon Dembo—to new three-year terms, with each nominee receiving a substantial majority of votes cast. Investors also approved, on a non-binding basis, the compensation of the company’s named executive officers and endorsed a non-binding recommendation that advisory “Say on Pay” votes be held every three years. With approximately 56% of outstanding shares favoring the triennial schedule, aligning with management’s preference, the board has adopted that cadence, meaning the next advisory vote on executive pay will occur at the company’s 2028 annual meeting, reinforcing the current leadership and compensation framework while providing less frequent but still regular shareholder oversight.

The most recent analyst rating on (VASO) stock is a Buy with a $0.19 price target. To see the full list of analyst forecasts on Vaso stock, see the VASO Stock Forecast page.

Vaso Sells Subsidiary VasoHealthcare IT to Nano-X

On November 19, 2025, Vaso Corporation announced its agreement to sell its subsidiary, VasoHealthcare IT Corp, to Nano-X Imaging Ltd. This decision follows a strategic review aimed at focusing on Vaso’s core operations. VasoHealthcare IT, a healthcare IT application reseller, contributes less than 5% of Vaso’s total revenue. The transaction, valued at up to $800,000, will allow Vaso to invest in its other business lines and strategic initiatives, while providing a promising future for VasoHealthcare IT under Nanox.